Delcath Systems, Inc. (DCTH)
| Market Cap | 559.00M +45.0% |
| Revenue (ttm) | 95.42M +35.8% |
| Net Income | 532,000 -76.2% |
| EPS | 0.01 -71.9% |
| Shares Out | 34.70M |
| PE Ratio | 1,095.92 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 703,094 |
| Open | 16.25 |
| Previous Close | 16.25 |
| Day's Range | 16.00 - 16.26 |
| 52-Week Range | 8.12 - 17.42 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 24.00 (+48.98%) |
| Earnings Date | Nov 3, 2026 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 48.98% from the latest price.
News
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems price target raised to $32 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $32 from $30 and keeps a Buy rating on the shares. The company raised its 2026 revenue guidance…
Delcath Systems Earnings Call Transcript: Q2 2026
Q2 revenue grew 21% year-over-year to $29.1M, driven by strong HEPZATO KIT sales and new center activations. Gross margin reached 90%, and full-year revenue guidance was raised to $104M-$108M, reflecting robust H1 performance and improved operational execution.
Delcath Systems Earnings release: Q2 2026
Delcath Systems released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Delcath Systems Quarterly report: Q2 2026
Delcath Systems has published its Q2 2026 quarterly earnings report on August 6, 2026.
Delcath Systems reports Q2 EPS 7c, consensus (9c)
Reports revenue $29.1M, consensus $26.26M. “Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZAT...
Delcath Systems sees positive adjusted EBITDA in FY26
The Company’s financial outlook for fiscal year 2026: Total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million, reflecting an increase in HEPZATO KIT volume of…
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial ...
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems to Host Second Quarter 2026 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems price target raised to $17 from $16 at BTIG
BTIG raised the firm’s price target on Delcath Systems (DCTH) to $17 from $16 and keeps a Buy rating on the shares as part of a broader research note previewing…
Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer
Delcath Systems (DCTH) announced that the first patient has been dosed at the European Institute of Oncology in Milan, Italy in its global Phase 2 clinical trial evaluating Hepzato in…
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the f...
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress
Delcath Systems (DCTH) announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical ...
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the...
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems presents new data on M-PHP at ESMO
Delcath Systems (DCTH) announced that new data from a retrospective analysis by independent investigators on percutaneous hepatic perfusion with melphalan using the CHEMOSAT Hepatic Delivery System wa...
Delcath Systems reports Q1 EPS (3c), consensus (9c)
Reports Q1 revenue $25M, consensus $23.41M. “We delivered a strong first quarter, marked by 20% volume growth over the prior quarter and a strong increase in new patient starts,” said…
Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M
Backs FY26 gross margin view 84%-87%.
Delcath Systems Earnings Call Transcript: Q1 2026
Record Q1 revenue and patient starts were driven by CHOPIN trial adoption and commercial expansion. 2026 guidance targets $100M+ revenue, with strong U.S. growth offsetting slower site activations and European reimbursement challenges.
Delcath Systems Earnings release: Q1 2026
Delcath Systems released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Delcath Systems Quarterly report: Q1 2026
Delcath Systems has published its Q1 2026 quarterly earnings report on May 7, 2026.
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial ...
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...